Acute in vivo resistance in high-dose therapy

Clinical Cancer Research

Volumn 4, Issue 2, 1998, Pages 483-491

  Teicher, Beverly A ^a,b   Ara, Gulshan ^a   Keyes, Susan R ^a   Herbst, Roy S ^a   Frei III, Emil ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; MELPHALAN; PACLITAXEL; THIOTEPA;

ALKYLATION; ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL SURVIVAL; COLONY FORMING UNIT GM; DRUG EFFECT; DRUG MEGADOSE; GROWTH INHIBITION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MELPHALAN; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PACLITAXEL; THIOTEPA;

EID: 0031912518     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Schabel, F. M., Griswold, D. P., Corbett, T. H., and Laster, W. R. Increasing therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Pharmacol. Ther., 20: 282-305, 1983.
2. Corringhma, R., Gilmore, M., and Prentice, H. G. High-dose melphalan with autologous bone marrow transplant: treatment of poor prognosis tumors. Cancer (Phila.), 52: 1783-1787, 1983.
3. Fay, J. W., Levine, M. N., and Phillips, G. L. Treatment of metastatic melanoma with intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and autologous marrow transplantation (AMTX). Proc. Am. Soc. Clin. Oncol., 17: 532, 1981.
4. Frei, III, E. Curative cancer chemotherapy. Cancer Res., 45: 6523-6537, 1985.
5. Frei, E., III, Antman, K., and Teicher, B. Bone marrow autotransplantation for solid tumors: prospects. J. Clin. Oncol., 7: 515-526, 1989.
6. Glode, L. M. Dose limiting extramedullary toxicity of high dose chemotherapy. Exp. Hematol., 7: 265-278, 1979.
7. Knight, W. A., III, Page, C. P., and Kuhn, J. G. High dose L-PAM and autologous marrow infusion for refractory solid tumors. Proc. Am. Soc. Clin. Oncol., 3: 150, 1984,
8. McElwain, T. J., Hedley, D. W., and Burton, G. Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan. Br. J. Cancer, 40: 72-80, 1979.
9. Peters, W. P., Eder, J. P., Henner, W. D., Schryber, S., Wilmore, D., Finberg, R., Schoenfeld, D., Bast, R., Gargone, B., Antman, K., Anderson, J., Anderson, K., Kriskali, M. S., Schnipper, L., and Frei, E., III. High-dose combination alkylating agents with autologous bone marrow support: a Phase I trial. J. Clin. Oncol., 4: 646-654, 1986.
10. Phillips, G. L., Fay, J. W., Herzig, G. P., Herzig, R. H., Weiner, R. S., Wolff, S. N., Lazarus, H. M., Karanes, C., Ross, W. E., and Kramer, B. S. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC 4366650 and cryopreserved autologous marrow transplantation for refractory cancer. Cancer (Phila.), 10: 1792-1802, 1983.
11. Thomas, E. D. The role of marrow transplantation in the eradication of malignant disease. Cancer (Phila.), 49: 1963-1969, 1982.
12. Ayash, L., Elias, A., Schwartz, G., Wheeler, C., Ibrahim, J., Teicher, B. A., Reich, E., Warren, D., Lynch, C., Richardson, P., Schnipper, L., Frei, E., III, and Antman, K. Double dose-intensive chemotherapy with autologous stem cell support for metastatic breast cancer: no improvement in progression free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J. Clin. Oncol., 14: 2984-2992, 1996.
13. Hill, R. P. Excision assays. In: R. F. Kallman (eds.), Rodent tumor models in experimental cancer therapy, pp. 67-75. New York: Pergamon Press, 1987.
14. Teicher, B. A. Preclinical models for high dose therapy. In: J. O. Armitage and K. H. Antman (eds.), High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells, pp. 14-42. Baltimore, MD: Williams & Wilkins, 1992.
15. Teicher, B. A., Northey, D., Yuan, J., and Frei, E., III. High-dose therapy/stem cell support: comparison of mice and humans. Int. J. Cancer, 65: 695-699, 1996.
16. Teicher, B. A., Holden, S. A., and Jacobs, J. L. Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity. Cancer Res., 47: 513-518, 1987.
17. Teicher, B. A., Herman, T. S., Holden, S. A., Wang, Y., Pfeffer, M. R., Crawford, J. M., and Frei, E., III. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science (Washington DC), 247: 1457-1461, 1990.
18. Teicher, B., Chatterjee, D., Liu, J., Holden, S., and Ara, G. Protection of bone-marrow granulocyte macrophage colony-forming units in mice bearing in vivo alkylating agent resistant EMT-6 tumors. Cancer Chemother. Pharmacol., 32: 315-319, 1993.
19. Frei, E., III, Teicher, B. A., Holden, S. A., Cathcart, K. N. S., and Wang, Y. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res., 48: 6417-6423, 1988.
20. Frei, E., III, Teicher, B. A., Cucchi, C. A., Rosowsky, A., Flatow, J. L., Kelley, M. J., and Genereux, P. Resistance to alkylating agents: basic studies and therapeutic implications. In: P. V. I. Woolley and K. D. Tew (eds.), Mechanisms of Drug Resistance in Neoplastic Cells, pp. 69-87. New York: Academic Press, 1988.
21. Teicher, B. A., and Frei, E., III. Development of alkylating agent-resistant human tumor cell lines. Cancer Chemother. Pharmacol., 21: 292-298, 1988.
22. Teicher, B. A., and Frei, E., III. Alkylating agents. In: R. S. Gupta (eds.), Drug Resistance in Mammalian Cells: Anticancer and Other Drugs, pp. 1-31. Boca Raton, FL: CRC Press, 1989.
23. Teicher, B. A., Holden, S. A., Herman, T. S., Alvarez Sotomayor, E., Khandekar, V., Rosbe, K. W., Brann, T. W., Korbut, T. T., and Frei, E., III. Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II). Int. J. Cancer, 47: 252-260, 1991.
24. Holden, S. A., Teicher, B. A., and Frei, E., III. Long-term persistence and cytokinetics of human tumor cells in vitro following high-dose alkylating agent exposure. Cancer Lett., 87: 211-222, 1994.
25. Holden, S., Teicher, B., Ayash, L., and Frei, E., III. A preclinical model for sequential high dose chemotherapy. Cancer Chemother. Pharmacol., 36: 61-64, 1995.
26. Holden, S., Emi, Y., Kakeji, Y., Northey, D., and Teicher, B. Host distribution and response to antitumor alkylating agents of EMT-6 tumor cells from subcutaneous tumor implants. Cancer Chemother. Pharmacol., 40: 87-93, 1997.